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CD163 interacts with TWEAK to regulate tissue
regeneration after ischaemic injury
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Macrophages are an essential component of the immune response to ischaemic injury and
play an important role in promoting inflammation and its resolution, which is necessary for
tissue repair. The type I transmembrane glycoprotein CD163 is exclusively expressed on
macrophages, where it acts as a receptor for haemoglobin:haptoglobin complexes. An
extracellular portion of CD163 circulates in the blood as a soluble protein, for which no
physiological function has so far been described. Here we show that during ischaemia, soluble
CD163 functions as a decoy receptor for TWEAK, a secreted pro-inflammatory cytokine of
the tumour necrosis factor family, to regulate TWEAK-induced activation of canonical nuclear
factor-kB (NF-kB) and Notch signalling necessary for myogenic progenitor cell proliferation.
Mice with deletion of CD163 have transiently elevated levels of TWEAK, which stimulate
muscle satellite cell proliferation and tissue regeneration in their ischaemic and
non-ischaemic limbs. These results reveal a role for soluble CD163 in regulating muscle
regeneration after ischaemic injury.
DOI: 10.1038/ncomms8792 OPEN
1 Department of Internal Medicine, Division of Cardiology, Emory University, Atlanta, Georgia 30322, USA. 2 Division of Cardiology, Cardiovascular Center,
Korea University Guro Hospital, Korea University College of Medicine, Seoul 152-703, Republic of Korea. 3 Kennesaw State University Department of Ecology,
Evolution, and Organismal Biology Kennesaw, Georgia 30144, USA. 4 Atlanta VA Medical Center, Atlanta, Georgia 30033, USA. 5 Coulter Department of
Biomedical Engineering at Georgia Tech and Emory, Atlanta, Georgia 30332, USA. 6 LSU Health Sciences Center, New Orleans, Louisiana 70112, USA.
Correspondence and requests for materials should be addressed to A.V.F. (email: avfinn@emory.edu).
NATURE COMMUNICATIONS | 6:7792 | DOI: 10.1038/ncomms8792 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
V
ascular disease is the major cause of limb amputation1.
Tissue hypoxia, resulting from narrowing of blood vessels,
attracts macrophages that play a critical role in tissue
repair2. Macrophages are a heterogeneous group of immune cells
that respond to pathophysiological cues to form distinct
functional phenotypes. In response to signals such as
lipopolysaccharide and interferon gamma (IFN-g), macrophages
undergo classical M1 activation expressing high levels of pro-
inflammatory cytokines, reactive oxygen species, and displaying
high microbicidal and tumoricidal activity. M2 macrophages are
stimulated by IL-4 and IL-13, express high levels of scavenging
molecules, dampen pro-inflammatory cytokine levels and
promote tissue remodelling3.
During tissue injury, M1 macrophages infiltrate the tissue first.
Subsequent infiltration of M2 macrophages not only dampens M1
pro-inflammatory responses but also promotes tissue repair.
Although M1/M2 dichotomy provides a conceptual framework
for our understanding of the function of macrophages in the
setting of injury, the mechanisms by which macrophages
orchestrate inflammation and its resolution to promote tissue
repair are incompletely understood.
M2 macrophages express high levels of CD163, a scavenger
receptor expressed exclusively on cells of the monocyte/macro-
phage lineage4. CD163 functions as a receptor for
haemoglobin:haptoglobin (Hb:Hp) complexes5. In addition,
shedding of the extracellular domain of CD163 from macro-
phages increases plasma levels of soluble CD163 (sCD163)6.
sCD163 shares B94% of the extracellular portion of membrane
bound CD163, covering its nine scavenger receptor cysteine-rich
domains7. Nevertheless, it displays relatively low affinity for
Hb:Hp complexes, suggesting its function may be unrelated to
haemoglobin scavenging7.
CD163 is generally considered an anti-inflammatory
molecule involved with resolution of inflammation because pro-
inflammatory stimuli such as lipopolysaccharide and oxidative
stress suppress its expression and promote its shedding7–9.
Moreover, CD163 expressing macrophages frequently are found
in areas of regenerating tissues after a ischaemic injury10.
However, the role of sCD163 in resolving inflammation and
promoting tissue regeneration is uncertain.
One potential mechanism by which CD163 might orchestrate
repair is through its interaction with the pro-inflammatory
cytokine tumour necrosis factor-like weak inducer of apoptosis
(TWEAK or TNFS12). TWEAK is mainly expressed by
leukocytes, including macrophages11. It is both a membrane
bound and soluble cytokine due to efficient cleavage by members
of the furin protease family12. TWEAK acts by binding to Fn14, a
highly inducible cell-surface receptor that is linked to several
intracellular signalling pathways, including nuclear factor-kB
(NF-kB), a pathway important in regulating responses to
inflammation13. Fn14 is expressed at relatively low levels in
many healthy tissues including tissue progenitor and endothelial
cells14. It is upregulated, however, in the setting of injury,
oxidative stress and inflammation15. In the setting of acute injury
TWEAK has been suggested to play a beneficial role in promoting
muscle repair through its effects on myogenic cells16. However,
little is known about the biological mechanisms regulating
TWEAK and the downstream pathways by which TWEAK
might orchestrate muscle regeneration.
Here we show that during periods of tissue ischaemia sCD163
functions as a decoy receptor for TWEAK to regulate its ability to
activate Notch signalling and stimulate myogenic progenitor cell
proliferation. Loss of CD163 in mice subjected to unilateral
femoral ligation resulted in transiently elevated levels of TWEAK,
activation canonical NF-kB and Notch signalling and enhanced
skeletal muscle regeneration not limited to the site of injury.
These findings demonstrate a novel mechanism by which
macrophages regulate tissue regeneration after ischaemic injury
through control of the pro-inflammatory cytokine TWEAK.
Results
Systemic tissue regeneration after injury in CD163 / mice.
To define the role of CD163 in the host response to ischaemic
injury, we subjected wild type (WT) and CD163 / mice to hind
limb ischaemia (HLI). HLI was induced by unilateral femoral
artery ligation. At baseline, WT and CD163 / mice not exposed
to femoral ligation demonstrated no differences in limb LASER
Doppler perfusion imaging (LDPI), capillaries (vascular endothe-
lial cadherin (VE-cadherin) immunostaining) or muscle fibres (b-
dystroglycan immunostaining) (Supplementary Fig. 1a,b). LDPI
showed that 14–28 days after ligation, CD163 deficiency sig-
nificantly increased blood flow in the ischaemic limb (IL) (Fig. 1a).
Unexpectedly, CD163 deficiency also significantly increased blood
flow to the contralateral non-ischaemic limb (NIL) in the same
post-ischaemic period (Fig. 1a). Supporting this, immunostaining
for VE-cadherin showed significant increases in the number of
capillaries per muscle fibre in both limbs (Fig. 1b,c). Moreover, we
found that the average size of muscle fibres in the gastrocnemius
muscle, as determined by b-dystroglycan immunostaining,
significantly decreased in both the IL and NIL of CD163 / mice
at 14 days post ligation, whereas no changes were seen in WT mice
(Fig. 1b,c). This difference in muscle morphology was no longer
present by 28 days even though the number of capillaries remained
higher (Fig. 1b,c).
To further characterize the response of CD163 / and WT
mice to HLI, we examined levels of myogenin, a muscle-specific
basic helix-loop-helix transcription factor important for myocyte
(early skeletal muscle precursor) development and myosin heavy
chain (MHC), an actin-based motor protein highly expressed in
mature skeletal muscle. Immunoblotting of ischaemic gastro-
cnemius muscles at 14 days after HLI demonstrated a significant
increase in myogenin and decrease in MHC in CD163 / mice,
while at 28 days there was significantly more MHC but similar
amounts of myogenin (Fig. 1d,e). Since these results suggest
greater myogenic cell precursor (that is, myoblast) predominance
in CD163 / mice at 14 days after HLI, we examined muscle
stem cell proliferation using antibodies against bromodeoxyur-
idine (Brdu), a marker of cell proliferation and Pax-7, a marker
for muscle satellite stem cells. Brduþ Pax7þ cells were
significantly and abundantly more present in 14 day IL of
CD163 / versus WT mice (Fig. 1f). Consistent with these
findings by 28 days after HLI both the IL and NIL of CD163 /
mice weighed significantly more than that of WT mice (Fig. 1g).
These results suggest stem cell-mediated muscle recovery is much
greater in CD163 / mice by 28 days after HLI.
To complete our evaluation, we measured necrosis in the
ischaemic gastrocnemius muscle and found it significantly
reduced at 14 days in CD163 / mice (Supplementary
Fig. 2a). Functional recovery was also examined on days 28
through 35 after HLI by measuring spontaneous running
distance. There was a significant and impressive difference
between CD163 / and WT mice in their running distance
response to ischaemic insult while sham-operated CD163 /
and WT mice ran a similar distance (Supplementary Fig. 2b).
These findings suggest that in CD163 / mice femoral ligation
results reduced tissue damage and enhanced functional recovery.
Myeloid CD163 controls skeletal muscle regeneration after HLI.
To determine whether myeloid CD163 deletion was responsible
for the phenotype of CD163 / mice after femoral ligation we
used bone marrow transplantation. We transplanted WT or
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CD163 / bone marrow cells into irradiated WT (referred to as
WT-WT and CD163 /-WT, respectively) or CD163 /
(WT-CD163 / and CD163 /-CD163 / , respectively)
recipients. We performed femoral ligation 6 weeks later.
Compared with WT-WT and WT-CD163 / , smaller
but more numerous numbers of muscle cells associated with
greater vascularity was observed in CD163 /-WT and
CD163 /-CD163 / 28 days after HLI as indicated by
staining for b-dystroglycan and VE-cadherin, respectively
(Supplementary Fig. 3a,b). We further characterized skeletal
muscle regeneration by performing immunoblotting of protein
from the IL of transplanted mice for myogenin and MHC.
As compared with WT-WT and WT-CD163 / , greater
myogenin but less MHC was observed in the skeletal muscle
of CD163 /-WT and CD163 /-CD163 / mice
(Supplementary Fig. 3c,d). These data demonstrate enhanced
muscle progenitor cell responses after HLI is conferred by CD163
deficiency in bone marrow cells.
Notch activation in CD163 / mice directs tissue regeneration.
To understand the mechanism of enhanced regeneration in
CD163 / mice, we examined retinal vascular patterning in
postnatal day 6 (P6) WT and CD163 / mice. P6 CD163 /
mice demonstrated increased vessel growth and stalk/connector
cell formation, but decreased tip cell branching and filopodia
(Supplementary Fig. 4a,b), a vascular pattern suggesting Notch
activation17. To confirm this, we demonstrated significantly
more lectin and Delta like ligand 4 (DLL4), a ligand for Notch
receptors, double-positive cells in P6 retinas of CD163 / mice
by immunohistochemistry (Supplementary Fig. 4c). Protein
generated from whole CD163 / and WT P6 retinas also
demonstrated increased levels of Notch intracellular domain
(NICD), a proteolytic cleavage product formed after ligand-
induced Notch activation, by immunoblotting (Supplementary
Fig. 4d).
Because Notch signalling appeared to play a major role in
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Figure 1 | CD163 / mice exhibit enhanced skeletal muscle repair in both ischaemic and NILs in response to femoral ligation. (a) Laser Doppler
analysis with perfusion quantitation 1, 4, 7, 14, 21 and 28 days after femoral ligation (n¼ 10 per group). (b,c) Immunostaining of NIL and IL for VE-cadherin
and b-dystroglycan (red) at 14 and 28 days after femoral ligation. The graphs below show the number of VE-cadherin positive cells/myofibre and the
average muscle fibre area. (n¼ 5 per each group). Scale bars, 100mm. (d) Immunoblotting of IL at 14 days after femoral ligation (n¼ 5 per group) with
quantitation of densitometry for MHC and myogenin. (e) Immunoblotting of IL at 28 days after femoral ligation (n¼ 5 per group) with quantitation of
densitometry for MHC and myogenin. (f) Immunostaining of IL for b-dystroglycan, Pax7 (blue) and Brdu (red) at 14 days after femoral ligation with
quantitation of average number of Pax7 Brdu positive cells (white arrows) per 10 high power field on right (n¼ 5 per each group). (g) Weight of NIL and IL
after femoral ligation (n¼ 5 per group). Comparisons between two groups were achieved using a two-sided student’s t-test. All bars show mean±s.e.m.
*Po0.05 versus WT.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8792 ARTICLE
NATURE COMMUNICATIONS | 6:7792 | DOI: 10.1038/ncomms8792 | www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
implicated in muscle progenitor cell proliferation, we examined
Notch activation in WT and CD163 / mice 14 days after
HLI17,18. Protein generated from the IL of CD163 / mice
showed significant upregulation of DLL4 and increases in
NICD by immunoblotting at 14 but not 28 days after HLI
(Fig. 2a,b). Because these tissue homogenates consist mainly of
skeletal muscle, we further confirmed Notch activation in
endothelial cells 14 days after HLI by immunostaining the IL
for DLL4 and VE-cadherin. There were significantly more DLL4/
VE-cadherin double-positive cells in the IL of CD163 / mice
(Supplementary Fig. 5). Both genotypes demonstrated no
difference in Notch signalling at baseline as indicated by
immunoblotting of skeletal muscle for NICD (Supplementary
Fig. 1c).
Because Notch signalling has been implicated in myogenesis
and is a context-dependent regulator of angiogenesis, we
examined whether blocking Notch signalling using the
g-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester) would inhibit the
phenotypic responses of WT and CD163 / mice to HLI17,18.
Treatment of CD163 / mice with DAPT completely inhibited
the myogenic and angiogenic responses of CD163 / mice to
HLI as indicated by LDPI, 14 day IL immunohistochemistry
for VE-cadherin and b-dystroglycan, and the number of
centrally located nuclei in myofibres (Fig. 2c–e). DAPT
treatment had no effect on blood flow recovery in WT mice
(Supplementary Fig. 6). Because Notch is not the only target of
g-secretase, we confirmed our observations using a blocking
antibody against DLL4. The DLL4 blocking antibody also
inhibited blood flow recovery and the angiogenic and muscle
morphologic responses of CD163 / mice at 14 days after HLI
(Supplementary Fig. 7). These data suggest that Notch signalling
mediates the effects of CD163 deletion on myogenesis and
angiogenesis after HLI.
Since Notch activation has been linked to changes in energy
metabolism and tissue regeneration after ischaemic injury likely
occurs in areas of hypoxia, we examined whether CD163
deficiency also led to changes muscle aerobic respiration19. We
isolated mitochondria from IL and NIL of mice 14 days post HLI.
A significant decrease in substrate oxidation was seen in State3 of
CD163 / mitochondria isolated from IL and NIL 14 days after
HLI compared with WT mice (Supplementary Fig. 8a,b,d,e),
indicating suppression of mitochondrial respiration. Using
quantitative PCR to analyse the IL after femoral ligation,
transcripts consistent with enhanced glycolytic activity such as
aldolase, galactose mutarose and hexokinase2 were significantly
elevated in the IL and NIL of CD163 / mice (Supplementary
Fig. 8c,f). There were no differences in either mitochondrial
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Figure 2 | Notch activation in CD163 / mice after ischaemic injury directs muscle regeneration. (a) Immunoblotting of IL at 14 days after femoral
ligation with quantitation of densitometry for NICD and DLL-4 (n¼ 5 per group). (b) Immunoblotting of IL at 28 days after femoral ligation with
quantitation of densitometry for NICD and DLL-4 (n¼ 5 per group). (c) LASER doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral
ligation with or without administration of Notch inhibitor DAPT (n¼ 5 per group). (d) Immunostaining for VE-cadherin and b-dystroglycan (red) in
CD163 / IL at 14 days after femoral ligation with or without DAPT administration. The graphs show the number of VE-cadherin positive cells/myofibre
and the average muscle fibre area. Scale bars, 100mm. (e) Immunostaining for b-dystroglycan (red) and TOTO-3 (blue) in CD163 / IL 14 days after
femoral ligation with or without DAPT administration. Scale bars, 20 um. The graph shows quantitation of regenerating myotubes in CD163 / ILs with or
without DAPT administration (n¼ 5 per group). All bars show mean±s.e.m. *Po0.05 versus WT in a. versus CD163 / con in c,d,e. Comparisons
between groups were achieved using a two-sided student’s t-test.
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CD163 deleted macrophages activate Notch signalling. Because
CD163 is a monocyte/macrophage-specific protein, we investi-
gated the phenotype and Notch activating ability of CD163 /
bone marrow-derived macrophages (BMM). Compared with WT
mice, BMM from CD163 / mice demonstrated increased
transcription of Notch ligands and transcriptional targets
including Notch-dependent M1 inflammatory genes such as
iNOS and IL-12 while markers of M2 macrophages such as
mannose receptor c type 1 (mrc1) and PPARg were unchanged
(Supplementary Fig. 9a)20. Immunoblotting of protein from
BMM demonstrated increased activation of NF-kB (that is, more
degradation of Ik-ba) and Notch (that is, NICD) (Supplementary
Fig. 9b).
To determine whether BMM from CD163 / mice could
activate Notch signalling in a paracrine fashion, cultured mouse
dermal endothelial cells (MDEC) were exposed to supernatants
from WT or CD163 / BMM for 3 h. As compared with WT
supernatants, CD163 / supernatants stimulated Notch signalling
as indicated by immunoblotting for NICD (Supplementary Fig. 9c).
Canonical NF-jB signalling activates Notch in CD163 / mice.
Because NF-kB has been linked to Notch activation through
upregulation of Notch ligands such as DLL4, we examined
whether CD163 / mice exhibit increased NF-kB activity by
examining both its canonical (p65/RelA) and non-canonical
(p100/52) pathways21–23. Immunoblotting of IL and NIL
14 days after femoral ligation demonstrated increased p65
phosphorylation and p52 presence in CD163 / mice
consistent with increased canonical and non-canonical activity
while at 28 days only non-canonical signalling was activated
(Fig. 3a,b). We then examined macrophage infiltration in the IL.
Immunohistochemistry (that is, anti-Mac-3 staining) demon-
strated greater macrophage accumulation and persistence in the
CD163 / IL (Fig. 3c).
To confirm that Notch activation in CD163 / mice was
mediated through NF-kB activation, we used the selective
canonical NF-kB inhibitor NBD, which blocks the interaction
of NEMO with IkB kinase complex24. NBD suppressed canonical
but not non-canonical NF-kB signalling in CD163 / IL and
inhibited the increased perfusion and Notch activation caused by
CD163 deficiency as detected by LDPI and immunoblotting,
respectively (Fig. 3d,e). NBD had no effect on blood flow recovery
in WT mice (Supplementary Fig. 10). To rule out an independent
effect of NBD on blood flow recovery or muscle morphology,
CD163 / mice were subjected to sham procedure and treated
with NBD or control for 14 days. No changes in either were seen
(Supplementary Fig. 11). These results suggest canonical NF-kB
signalling mediates Notch activation and the response of
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Figure 3 | Canonical NF-jB signalling mediates Notch activation and the response of CD163 / mice to HLI. (a) Immunoblotting of IL 14 days
after femoral ligation (n¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated (p-p65)/total p65 (T-p65) and p52.
(b) Immunoblotting of IL 28 days after femoral ligation (n¼ 5 per group) with graphs showing quantitation of densitometry for phosphorylated (p-p65)/
total p65 (T-p65) and p52. (c) Immunostaining for Mac-3 (red) of IL of WT and CD163 / mice 3 and 5 days after femoral ligation. Scale bars, 100mm.
The graph shows the timecourse of Mac-3 staining (n¼ 5 per group). (d) Laser Doppler analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral
ligation with administration of scrambled control peptide (control) or NF-kB inhibitor NBD (n¼ 5 per group). (e) Immunoblotting of CD163 / IL at 14
days after femoral ligation with administration of scrambled control peptide (control) or NF-kB inhibitor (NBD) (n¼ 5 per group) with bar graphs showing
quantitation of densitometry for phosphorylated/total p65, p52 and NICD on right. All bars show mean±s.e.m. *Po0.05 versus WT in a–c; versus
CD163 / control in d,e. Comparisons between groups were achieved using a two-sided student’s t-test.
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TWEAK mediates the response of CD163 / mice to HLI.
TWEAK is mainly expressed by leukocytes and becomes a soluble
cytokine when cleaved by members of the furin protease family.
TWEAK is known to induce NF-kB and in some contexts, such
as cardiotoxin-induced muscle injury, promotes transient
inflammation and may play a role in muscle regeneration16.
Conversely, sustained TWEAK expression through transgenic
overexpression can promote muscle pathology and impede the
regenerative capacities of skeletal muscle25. Using a combinatorial
peptide library, Bover et al.26 previously identified a potential
protein–protein interaction between CD163 and TWEAK. We
measured TWEAK and sCD163 concentrations in plasma
obtained from both genotypes of mice after HLI. Compared
with non-ligated WT and CD163 / mice and with WT mice
after femoral ligation, the plasma of CD163 / mice after limb
ligation contained significantly higher levels of TWEAK at 14 but
not 28 days (Fig. 4a). Additionally, the amount of plasma sCD163
was significantly increased in WT mice 3 days after HLI (Fig. 4a).
(Plasma sCD163 was not present in CD163 / mice.) Thus,
CD163 / mice demonstrate transiently elevated levels of
TWEAK, which contrasts with previous experiments in which
chronic TWEAK overexpression has been linked to muscle
degradation25.
To examine whether TWEAK was essential in the phenotype of
CD163 / mice, we treated them with either a TWEAK
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Figure 4 | TWEAK activates canonical NF-jB signalling and Notch activation and mediates the response of CD163 / mice to HLI. (a) Analysis of
plasma from WT and CD163 / mice before and after femoral ligation for TWEAK and sCD163 levels by ELISA (n¼ 5 per group). (b) Laser doppler
analysis of CD163 / mice 3, 7, 14, 21 and 28 days after femoral ligation administered an isotype control or TWEAK blocking antibody (n¼ 5 per group).
(c) Immunoblotting of CD163 / IL at 14 days after femoral ligation with administration of isotype control or TWEAK blocking antibody (n¼ 5 per group)
with graphs showing quantitation of densitometry for phosphorylated/total p65 and NICD below. (d) Immunostaining for VE-cadherin (green) and b-
dystroglycan (red) in CD163 / limbs with 14 day administration of TWEAK (5 or 25mg kg 1 day 1) or saline (control) (n¼ 5 per group). Scale bars,
100mm. The graphs show the number of VE-cadherin positive cells/myofibre and the average muscle fibre area. (e) Immunoblotting of CD163 / limbs
with 14 day administration of TWEAK (5 or 25mg kg 1 day 1) or saline (control) (n¼ 5 per group) with graphs showing quantitation of densitometry for
phosphorylated p65/total p65, p52 and NICD. All bars show mean±s.e.m. *Po0.05 versus WT in a; versus CD163 / control in b,c and e. Po0.05
versus other groups in d,e. Comparisons between groups were achieved using a two-sided student’s t-test. For multiple group comparisons, we utilized a
one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post hoc analysis of differences between groups was made using a
Tukey–Kramer honest significance difference test.
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blocking antibody inhibited the increased perfusion caused by
CD163 deficiency (Fig. 4b) but had no effect in WT mice
(Supplementary Fig. 12). To confirm TWEAK was involved in the
activation of canonical NF-kB signalling and Notch seen in
CD163 / mice, immunoblotting for phosphorylated and total
p65 and NICD of protein from the IL of control and TWEAK
blocking antibody-treated mice was performed at 14 days post
HLI. The TWEAK antibody prevented activation of both
signalling pathways (Fig. 4c). These data provide evidence that
TWEAK is responsible for Notch and canonical NF-kB activation
in CD163 / mice after HLI.
TWEAK infusion into CD163 / and WT mice. To explore
whether TWEAK infusion could reproduce the effects seen in
CD163 / mice at 14 days, we administered recombinant
mouse TWEAK (Arg105-His249 with His Tag) or saline control
into CD163 / naive mice and examined skeletal muscle 14
days later. TWEAK was given in two separate dosing strategies
based upon previous work showing it to have a biphasic effect on
cultured skeletal muscle with lower doses (10 ng ml 1) inducing
non-canonical NF-kB activation and higher doses (100 ng ml 1)
inducing both canonical and non-canonical pathways27. Low
doses of TWEAK (5 mg kg 1 day 1) did not appreciably change
skeletal muscle morphology or vascularity and activated only
non-canonical NF-kB signalling (that is, p52) in skeletal
muscle (Fig. 4d,e). By contrast, higher doses of TWEAK
(25 mg kg 1 day 1) significantly increased skeletal muscle
vascularity and decreased skeletal muscle size (Fig. 4d).
Moreover, it also activated both canonical and non-canonical
NF-kb signalling, Notch activation, and increased myogenin as
detected by immunoblotting of limbs (Fig. 4e). These changes are
consistent with those seen in CD163 / muscle 14 days after
HLI as well as previous data, in which muscle-specific transgenic
overexpression of TWEAK-reduced muscle differentiation25. Our
data suggest that high doses of TWEAK are able to stimulate
muscle progenitor cell proliferation through activation of
canonical NF-kB and Notch signalling, and thereby delay
muscle differentiation. To determine whether CD163 is critical
in mediating the biological effect of TWEAK, we administered
low- and high-dose TWEAK to WT mice for 14 days. TWEAK
had no effect on skeletal muscle morphology, vascularity or
molecular signalling (Supplementary Fig. 13). Lastly, we
determined whether high doses of TWEAK could also
reproduce the changes in mitochondria seen in CD163 /
mice after HLI. TWEAK infusion was able to decrease
mitochondrial respiration in skeletal muscle. (Supplementary
Fig. 14).
TWEAK-mediated canonical NF-kB signalling activates Notch.
To further confirm the effects of TWEAK on both MDEC and
myoblast cells, respectively, we examined the effects of both low-
and high-dose TWEAK on cultured MDEC and C2C12 cells. In
both cells lines only higher doses of TWEAK-activated canonical
NF-kB signalling and Notch activation (NICD) as detected by
immunoblotting (Fig. 5a,b). Next, to confirm that canonical
NF-kB signalling was responsible for Notch activation, we
transfected cells with siRNA against p65, treated them with
TWEAK and examined NICD by immunoblotting. Knockdown
of p65 completely inhibited the activation of Notch signalling by
TWEAK in both cell lines (Fig. 5c,d). Lastly, we evaluated the
effect of TWEAK on MDEC and C2C12 proliferation and the
effect of siRNA directed knockdown of p65 and RBPJ, a major
transcriptional effector of Notch. TWEAK increased cell pro-
liferation in both cell lines as detected by BrdU assay which was
inhibited by treatment with siRNA against p65 and RBPJ
(Fig. 5e–h). These results suggest high doses of TWEAK-induced
stimulation of canonical NF-kB activates Notch signalling which
mediates the proliferative muscle and endothelial responses
seen in CD163 / mice at 14 days.
sCD163 inhibits the effect of TWEAK. Next we examined
interaction between TWEAK and CD163 using a recombinant
mouse CD163 (mCD163) protein which encompasses all nine
scavenger receptor cysteine-rich domains of CD163 and thus
mimics the structure of sCD163. We confirmed TWEAK binding
abilities of CD163 via ELISA. Plates were coated with mCD163,
mouse Fn14 (positive control) or mouse VE growth factor
receptor 1 (VEGFR1, negative control). As seen in Fig. 6a,
TWEAK demonstrated increased binding to both mCD163 and
FN14 as compared with VEGFR1. Next, we evaluated whether
TWEAK would bind to both CD163 and FN14 in a dose-
dependent manner. Although TWEAK did bind to both recep-
tors, it seemed to have slightly greater affinity for FN14 than
CD163 (Fig. 6b). Next, we determined whether mCD163 was able
to inhibit the biological effects of TWEAK on NF-kB signalling in
mouse endothelial cells. Increasing doses of CD163 were added to
endothelial cells in combination with TWEAK (200 ng ml 1). As
seen in Fig. 6c, concentration ratios of CD163: TWEAK at or
greater than 50 inhibited TWEAK-induced canonical and non-
canonical NF-kB signalling. (Because previous data has shown
that epitope tags on TWEAK might affect its biological behaviour
(that is, ability to activate canonical NF-kB signalling pathways)
via oligomerization, untagged recombinant mouse TWEAK was
used for experiments in Fig. 6b,c (ref. 28). Overall no difference
was found between His tagged and untagged recombinant mouse
TWEAK in terms of their NF-kB activating ability in mouse
endothelial cells). To investigate the interaction between CD163
and TWEAK in vivo, we immunoprecipitated TWEAK from the
serum of mice before and after HLI and immunoblotted for
CD163. Immunoprecipitation showed CD163/TWEAK
complexes circulate in the serum of WT mice (Fig. 6d). Our
recombinant sCD163 protein ran at a slightly higher molecular
mass (B130 kDa) than the native protein (110 kDA). This is
consistent with heavy glycosylation as it is expressed in a mouse
myeloma cell line (NS0 cells). To support a biological role for a
TWEAK-CD163 interaction, we examined the effect of high-dose
TWEAK infusion in CD163 / mice on skeletal muscle mor-
phology and molecular signalling in the absence and presence of
mCD163. mCD163 inhibited the increased muscle regeneration,
NF-kB and Notch activation caused by TWEAK infusion alone
(Fig. 6e,f). To rule out an independent effect of sCD163 on these
end points we administered mCD163 to naı̈ve CD163 /
animals for 14 days and analysed muscle morphology and
angiogenesis by immunohistochemistry for b-dystroglycan for
VE-cadherin. sCD163 had no effect on either (Supplementary
Fig. 15). These data indicate sCD163 is able to inhibit the bio-
logical effects of TWEAK.
Discussion
Here we show that during periods of tissue ischaemia, macro-
phages release TWEAK to induce myogenic progenitor cell
proliferation through activation of canonical NF-kB and Notch
signalling. Subsequently sCD163 scavenges TWEAK to inhibit its
ability to activate this pathway thereby promoting muscle
differentiation. Loss of CD163 in mice resulted in transiently
elevated levels of TWEAK-mediated activation of canonical NF-
kB and Notch signalling in both the ischaemic and NILs which
stimulated muscle satellite cell proliferation. Subsequent decreases
in TWEAK and Notch signalling activation allowed progenitor
differentiation which led to enhanced skeletal muscle
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regeneration not limited to the site of injury. Our findings
highlight a novel mechanism by which macrophages coordinate
tissue repair in ischaemia-injured skeletal muscle.
CD163 was first identified as a macrophage-specific scavenger
receptor for Hb:Hp complexes5. In addition to its membrane
bound form, a soluble variant of CD163 (that is, sCD163) exists
in the plasma as well as other tissue fluids. sCD163 demonstrates
relatively low affinity for Hb:Hp as compared with the membrane
bound form, suggesting alternative functions for this receptor7.
Using a combinatorial peptide library, Bover et al.26 first
identified a potential interaction between CD163 and TWEAK.
Although existing studies suggest that sCD163 may be a valuable
diagnostic marker to monitor disease progression, definitive
biological evidence for this interaction has been lacking in part
due to lack of relevant animal model29. Here we use CD163-
deficient mice to demonstrate for the first time an important
biological role for sCD163 in the setting of tissue ischaemia. By
binding to and inactivating TWEAK, sCD163 plays an essential
role in (1) preventing TWEAK from mediating tissue
regeneration in areas remote from the site of injury and
(2) limiting the duration of TWEAK-induced activation of
canonical NF-kB/Notch thereby limiting progenitor cell
proliferation and promoting their differentiation. Recently, Fick
et al.30 challenged the initial findings of Bover by demonstrating
equal binding of recombinant TWEAK to CD163 expressing or
empty vector transfected Hek293 cells. One potential and
important difference between our own studies and those of Fick
pertain the use of recombinant sCD163 peptide. Fick’s assays
mostly examined the ability of membrane bound CD163 to bind
TWEAK rather than the soluble form. As demonstrated by
Moller et al.7, the affinities of membrane bound and sCD163 for
target proteins such as Hb:Hp are very different probably due to
lack of receptor cross-linking (on the soluble version). Further
studies of the affinity of membrane bound versus sCD163 for
TWEAK are likely need to further investigate this.
TWEAK is both a membrane bound and a soluble pro-
inflammatory cytokine known to activate NF-kB signalling
through binding to its receptor Fn14 which is highly expressed
on mesenchymal progenitor cells in including those of muscle
lineage. Some studies have suggested that the membrane bound
version of TWEAK as well as aggregates of soluble TWEAK have
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Figure 5 | High-dose TWEAK activates canonical NF-jB and Notch signalling which stimulates cell proliferation in cultured endothelial and myoblast
cells. (a) Immunoblotting of MDEC with or without administration of TWEAK (10 or 150 ng ml 1) (n¼4 per group) for the indicated proteins.
(b) Immunoblotting of C2C12 cells with or without administration of TWEAK (10 or 100 ng ml 1) (n¼4 per group) for the indicated proteins.
(c) Immunoblotting of MDEC transfected with scramble or p65 siRNA and treated with nothing or TWEAK (150 ng ml 1), (n¼4 per group) for NICD.
(d) Immunoblotting of C2C12 cells transfected with scramble or p65 siRNA and treated with nothing or TWEAK (100 ng ml 1) (n¼4 per group) for NICD.
(e) BrdU proliferation assay of MDEC treated with 150 ng ml 1 TWEAK (n¼ at least four per experiment repeated twice). (f) BrdU proliferation assay of
C2C12 treated with 100 ng ml 1 TWEAK (n¼ at least four per experimental group repeated twice). (g) BrdU proliferation assay of MDEC treated with
TWEAK (150 ng ml 1) in the presence of scramble siRNA or siRNAs against p65 or RBPJ (n¼ at least four per experimental group repeated twice).
(h) BrdU proliferation assay of C2C12 treated with TWEAK (100 ng ml 1) in the presence of scramble siRNA or siRNAs against p65 or RBPJ (n¼ at least
four per experimental group repeated twice). All bars show mean±s.e.m. *Po0.05 versus other groups. Comparisons between groups were achieved
using a two-sided student’s t-test. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more
detailed post hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test.
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opposed to soluble TWEAK trimers28,31. Although we cannot
rule out the involvement of membrane bound TWEAK in the
changes seen after HLI in CD163-deficient mice, this seems less
likely as exposure of mouse endothelial cells to cell free
supernatants from CD163-deficient mouse macrophages were
able to activate Notch signalling (which requires canonical NF-kB
activation) (Supplementary Fig. 9c). However, given the relatively
low plasma concentration of serum soluble TWEAK
(100 pg ml 1) after HLI and the low affinity of sCD163 for
soluble TWEAK, it remains possible that macrophage expressed
CD163 acts by inhibiting macrophage expressed membrane
TWEAK. To what extent aggregates of TWEAK might play a role
in its biological activity in vivo remains unclear and deserves
further investigation.
Previous studies of TWEAK in the context of muscle injury
have shown varying effects with some suggesting TWEAK may
contribute to muscle repair in the setting of an acute injury16.
Other studies demonstrate opposite effects of TWEAK in the
setting of chronic TWEAK overexpression which appeared to
inhibit the regenerative capacities of muscle tissue25. More recent
studies even suggest TWEAK impedes muscle renewal through
inhibition of Notch signalling and satellite cell numbers in
myofibre cell explants32. How do we resolve these apparent
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Figure 6 | sCD163 inhibits the effect of TWEAK on tissue regeneration. (a) TWEAK (100 ng ml 1) was added to VEGFR1, Fn14 or CD163-coated wells.
Bound protein was measured by ELISA using an antibody to detect TWEAK. (b) Fn14 or CD163 were coated onto 96-well plates and incubated with
increasing doses of untagged TWEAK. Bound protein was measured by ELISA. (c) Immunoblotting of MDEC stimulated with TWEAK at 200 ng ml 1
(which activates both canonical and non-canonical NF-kB signalling) and increasing doses of recombinant mouse sCD163 for the indicated proteins.
(d) Immunoprecipitation of serum before and after femoral ligation using anti-TWEAK antibody with immunoblotting for CD163. (The figures show a
representative blot with a total of four experiments conducted.) (e) Immunostaining for VE-cadherin and b-dystroglycan (red) in limbs of CD163 / mice
treated for 14 days with saline (control), TWEAK administration (25 mg kg 1 day 1 administered via Alzet pump) alone or in combination with sCD163
administration (25mg kg 1 day 1 administered by intraperitoneal injection) (n¼ 5 per group). The graphs show the number of VE-cadherin positive
cells per myofibre and the average muscle fibre area per group. (f) Immunblotting of CD163 / limb after 14 days of TWEAK administration
(25mg kg 1 day 1 administered via Alzet pump) alone or in combination with sCD163 administration (25 mg kg 1 day 1 administered by intraperitoneal
injection) (n¼ 5 per group). O.D., optical density. Bar graphs show quantitation of densitometry for phosphorylated to total p65, p52 and NICD. *Po0.05
versus other groups. For multiple group comparisons, we utilized a one-way ANOVA. If the variance ratio test (F-test) was significant, a more detailed post
hoc analysis of differences between groups was made using a Tukey–Kramer honest significance difference test. For binding experiments, average of at least
four well per group shown with each experiment repeated at least two times with representative results shown.
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muscle repair in the setting of ischaemic injury in CD163-
deficient mice? In the present study, we demonstrate the
importance of sCD163 in determining TWEAK levels and
biological activity. Transient upregulation of TWEAK induced
by CD163 deficiency at day 14 after HLI increased canonical NF-
kB and Notch activation which was associated with myogenic
progenitor cell proliferation. By 28 days TWEAK levels, Notch
activation, and canonical NF-kB signalling were no longer
different between WT and CD163-deficient mice although non-
canonical signalling remained higher (Fig. 7). This appears to
have allowed the differentiation of early myogenic progenitors
(that is, myoblasts) into mature cells as indicated by histology,
MHC levels, and prior data which supports a role for non-
canonical NF-kB signalling in myoblast fusion27. Although we
did not specifically examine the effect of lower doses of TWEAK
on satellite cell behaviour, Ogura et al.32 recently found that lower
doses of TWEAK (10 ng ml 1) actually inhibited some Notch
transcriptional targets such as Hey1 and HeyL in cultured
myoblasts. We did not detect any changes in Notch activation as
measured by NICD in both the in vitro and in vivo settings under
similar dosing conditions, although it remains possible that lower
doses of TWEAK might repress Notch signalling to promote
myogenic precursor cell differentiation. This is not inconsistent
with our findings in CD163 / mice that decreasing levels of
TWEAK between 14 and 28 days after HLI coincided with muscle
differentiation as evidence by increases in MHC. We also do not
dispute that more prolonged TWEAK expression, as shown by
others, might impede regenerative capacities of muscle through
mechanisms that likely involve prolonged NF-kB-mediated
inflammation and mitochondrial dysfunction.
In addition, recent findings in TWEAK knockout mice in the
setting of muscle injury deserve to be addressed. Mittal et al.25
found that genetic deletion of TWEAK increased muscle fibre
cross-sectional area and levels of MHC in regenerating muscle,
while myoblasts from mice with muscle-specific transgenic
overexpression of TWEAK showed reduced differentiation. This
data is not inconsistent with our findings that demonstrate high
doses of TWEAK promote muscle proliferation and delay
differentiation (as seen in CD163 / mice 14 days after HLI
or after high-dose TWEAK infusion), while its absence likely
promotes muscle differentiation (similar to what we see 28 days
after HLI in CD163 / mice). Ogura et al.32 also reported that
TWEAK knockout mice demonstrate increased Pax7þ cells and
increase in some Notch transcriptional targets after cardiotoxin-
induced injury, findings which would seem to contradict our own
work suggesting high doses of TWEAK activate Notch signalling
and Pax7 cell proliferation. However, one important caveat of
Ogura et al.11 findings is the reduced overall inflammation seen in
TWEAK-deficient mice leaves open the possibility that
inflammatory mediators other than TWEAK might be
responsible for these findings.
A link between NF-kB and Notch signalling has been suggested
by others in the setting of cancer as well as in mice with mutant
endothelial cell-specific NF-kB (dominant negative Ik-ba)22,23.
How does canonical NF-kB signalling activate Notch pathways?
Although not specifically explored here, the effect of NF-kB on
Notch activation may in part be mediated through increased
expression of the Notch ligand DLL4 and Notch1 receptor each of
which has a canonical NF-kB binding motif (5-GGRRNNYYCC)
in their promoters. Further support for this concept is suggested
by our data showing that a specific DLL4 blocking antibody could
inhibit the angiogenic and regenerative responses of CD163 mice
to HLI.
The effect of Notch signalling in postnatal myogenesis has been
well-studied and demonstrates satellite cell activation, prolifera-
tion and cell lineage determination are regulated by Notch
signalling18. Thus our results that activation of Notch in muscle
tissue is associated with satellite cell proliferation and myoblast
predominance at 14 days after HLI is in accordance with these
results. The role of Notch signalling in postnatal vascular
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Figure 7 | CD163-TWEAK interaction controls skeletal muscle recovery after ischaemic injury. After ischaemic injury, macrophages secrete TWEAK
which induces tissue canonical NF-KB/Notch mediated myogenic progenitor cell proliferation. TWEAK’s biological activity is tightly regulated by sCD163
binding which limits serum TWEAK levels and leads to resolution of canonical NF-kB/Notch activation at the site of injury, allowing for cell differentiation.
In the absence of sCD163 (as seen in CD163-deficient mice), TWEAK levels are systemically elevated and TWEAK’s biological effect is unopposed leading
to prolonged activation of NF-kB and Notch signalling which causes greater myogenic progenitor cell proliferation-induced myogenesis not limited to the
site of injury.
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homeostasis is less well understood. In retinal vascular
development endothelial cells within a developing blood vessel
sprout utilize the Notch signalling pathway to coordinate cellular
behaviours during angiogenesis17. Notch receptor activation
appears to occur primarily in ‘connector’ or stalk cells while
‘tip’ cells locating at the leading edge of an angiogenic front
migrate and branch. In various models of angiogenesis including
HLI, inhibition of Notch signalling promotes vascular sprouting,
failure of tip cell fusion and dysfunctional vasculature23,33.
Although we did not specifically measure vascular branching in
the HLI model, our data suggest that Notch activation in
endothelial cells can promote the development of functional
vasculature. CD163-deficient animals receiving the Notch
inhibitor DAPT or an anti-DLL4 blocking antibody
demonstrate inhibition of blood flow recovery and angiogenesis
after HLI and underscore that Notch signalling in endothelium of
adult mice can promote functional angiogenesis.
Our findings reveal the importance of macrophage sCD163 in
regulating tissue regeneration after ischaemic muscle injury. Loss
of CD163 in mice resulted in transiently elevated levels of
TWEAK-mediated activation of NF-kB and Notch signalling in
both the ischaemic and NILs of CD163 / mice which led to
enhanced myogenesis/angiogenesis not limited to the site of
injury. The increased NF-kB and Notch activation seen in the
ischaemic and NILs of these mice did resolve by 28 days after
HLI, leading to cellular differentiation and enhanced regenera-
tion. These data highlight the importance of both inflammation
and its resolution in proper tissue regeneration and critical role of
the CD163-TWEAK interaction in this process. The CD163-
TWEAK pathway we have identified in the setting of limb
ischaemia may be a novel target for regenerative therapies.
Methods
Animals. The Institutional Animal Care and Use Committee at Emory University
approved all animal protocols. All animal experiments were conducted according
to the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. CD163 knockout mice (CD163tm1(KOMP)Vlcg) were generated using tar-
geting constructs available from the University of California at Davis International
Mouse Consortium (KOMP). Mice were generated by the Emory transgenic mouse
core on a C57BL6 background. WT (that is, C57BL6) mice used for all experiments
were littermate controls. Male mice 8 weeks of age were used for all experiments.
Experimental animal protocols. For studies of Notch signalling, WT or
CD163 / mice were randomized in two groups: mice subjected to intra-
peritoneal administration of carrier (controls, n¼ 5); or Notch inhibitor DAPT
(10 mg kg 1 day 1, n¼ 5) every other day for 14 or 28 days after HLI. DAPT was
initially dissolved in dimethylsulphoxide to make a stock solution and then
resuspended in 10% ethanol 90% corn oil as previously described34. For
experiments involving inhibition of Notch signaling with a DLL4 blocking
antibody (BioLegend) or the LEAF-purified DLL4 blocking antibody (BioLegend),
antibodies were administered at an approximate dose of 250 mg twice weekly by
intraperitoneal injection for 14 or 28 days after HLI. The dosing was based upon
previous studies35. For experiments involving inhibition of NF-kB signalling,
CD163 / mice were randomized into two groups: mice subjected to
intraperitoneal administration with IKK-NBD control peptide (100 mg day 1,
n¼ 5, Enzo Life Sciences); or NF-kB inhibitor NBD (100 mg kg 1 day 1, n¼ 5,
Enzo Life Sciences) daily for 14 days after HLI. For LDPI experiments using NBD,
animals received either control peptide or NBD (100 mg kg 1 day 1) via Alzet
pump (Model 2800) for 28 days. Dosing was based upon previous studies24. For
experiments involving inhibition of TWEAK signalling, CD163 / mice were
randomized into two groups: mice subjected to intraperitoneal administration with
LEAF-purified isotype control (Biolegend, n¼ 5), or TWEAK blocking antibody
(BioLegend clone MTW-1, 1 mg kg 1 day 1, n¼ 5) daily for 14 days after HLI.
For LDPI experiments using isotype control or TWEAK blocking antibody,
animals received either control or anti-TWEAK antibody (1 mg kg 1 day 1)
intraperitoneally for 28 days. Dosing was based upon manufacturers
recommendation. For studies involving recombinant mouse TWEAK
administration, WT or CD163 / mice were randomized into three groups: mice
subjected to administration of phosphate-buffered saline (PBS) (control) via Alzet
pump (Model 2800), mice subjected to administration of low dose TWEAK via
Alzet pump (5 mg kg 1 day 1, n¼ 5), or high-dose TWEAK (25mg kg 1 day 1,
n¼ 5) via Alzet pump. For studies involving administration of CD163 peptide with
and without recombinant high-dose mouse TWEAK-CD163 / mice were
administered either high-dose TWEAK as described above or both mCD163
(25 mg kg 1 day 1 delivered by once daily by intraperitoneal injection) and high-
dose TWEAK via Alzet pump (Model 2800). This resulted in concentration ratios
of CD163: TWEAK of B89 as determined by ELISA. For experiments involving
administration of NBD into sham-operated CD163 / mice or mCD163 into
naive mice dosing was as stated above. Animals were randomly assigned to study
groups for in vivo studies; no formal randomization method was applied when
assigning animals for treatment. No blinding was used.
BM transplantation. Bone marrow transplantation was conducted as previously
reported36. Briefly, bone marrow was obtained from 8-week-old CD163 / and
littermate WT donor mice by flushing femurs and tibiae with RPMI 1640 medium.
Recipient mice were 8-week-old CD163 / or WT mice. Recipients were
irradiated with 1,100 rads and then were immediately reconstituted with either
2 106 CD163 / or WT bone marrow cells via retro orbital injection. Eight
weeks later, spleen samples of some recipient CD163 mice were analysed for
western blotting.
Hind limb ischaemia model. At 8 weeks of age, animals were anesthetized with
2% isofluorane through a nose cone. Using aseptic technique, left superficial
femoral artery was ligated proximal to the caudally branching deep femoral artery
and proximal to the branching of the tibial arteries. The length of the artery was
excised between the two ligation points, leaving the femoral nerve intact. The skin
was closed with monofilament sutures. To measure blood flow, LDPI was per-
formed as described previously37. Briefly, mice were anesthetized by inhalation of
2% isofluorane and scanned with the LDPI system (PIM II Laser Doppler Perfusion
Imager). Functional recovery of the IL was assessed by monitoring of spontaneous
activity in cages equipped with a running wheel.
Histology and Immunohistochemistry. We injected 10 ml of Dulbecco’s PBS/
Heparin (10 unit per ml), 10 ml of vasodilation solution (100 mM adenosine, 10mM
sodium nitroprusside and 0.05% bovine serum albumin directly dissolved in
Dulbecco’s PBS with Ca2þMg2þ ) and 10 ml of 4% paraformaldehyde solution
consecutively at a rate of 10 ml min 1 into left ventricle of the heart. Gastro-
cnemius muscles were collected after perfusion fixation. Tissue samples were
transferred into 15% sucrose solution and incubated at 4 C for 2–3 h, followed by
incubation in 30% sucrose solution at 4 C overnight. Tissue samples were
embedded in optimal cutting temperature compound and frozen, followed by
sectioning at 15mm thickness for limb samples. Sections were incubated in primary
antibodies b-dystroglycan at a dilution of 1:250 (cat. #: ab49515 Abcam), Mac-3 at
a dilution of 1:100 (Cat #: 553322 BD Pharmingen), VE-cadherin 1:250 (cat #:
ab33168 Abcam), DLL4 at a dilution of 1:50 (cat #: AF1389, R&D Systems), Pax7 at
a dilution of 1:250 (Cat No: ARP32742, Aviva Systems Biology) for 24 h at 4 C and
fluorescently labelled secondary antibody if required donkey anti-mouse IgG 546
nm (Cat. No: A10036, Invitrogen) and donkey anti-mouse IgG 488 nm (Cat. No:
A21202, Invitrogen). Tissue samples were mounted on slides with Vectashield
mounting medium (Vector Labs, Burlingame, CA). TOTO-3 (Invitrogen) was used
as a nuclear counterstain (Invitrogen). Tissue was visualized using objective on a
Nikon Eclipse TE- 2000U microscope (Nikon, Tokyo, Japan) with HeNe laser, and
driven by EZ-C1 Viewer v3.5 software (Nikon). Projection images were generated
by collecting the maximum pixel intensity from each image of the Z stack and by
projecting pixel intensity onto the single (projection) image. The area and per-
centage of staining was quantified using NIS-elements v3.0 (Nikon). Staining area
was quantified using computer-aided planimetry and was expressed as a percentage
of the total surface area of the tissue section. The area of gastrocnemius muscle was
quantified using by manually outlining cells with contiguous b-dystroglycan.
Necrotic area in the gastrocnemius muscle was analysed by haematoxylin and eosin
staining. Necrotic cells display a more glassy homogeneous appearance in the
cytoplasm with increased eosinophilia.
Analysis of limb regeneration. BrdU (100 mg kg 1 cat #: 2760 Millipore) was
injected intraperitoneally every day from 7 to 14 days after HLI. Gastrocnemius
muscles were removed 14 days. Immunofluorescence was performed using anti-
bodies against BrdU, b-dystroglycan and Pax7 as described above. Data was
expressed as the average number of BrdU Pax7 positive cells per 10 high power
fields. As a measure of regeneration efficacy, we also counted the number of
centrally nucleated regenerating myofibres 14 days after HLI.
Immunoblotting and quantitative PCR with reverse transcription. Protein was
processed and separated on polyacrylamide gel as previously reported38. Blot
membranes were incubated with commercially available antibodies against DLL-4
(cat# AF1389 R&D Systems), NICD (cat #4147 Cell Signalling), Ikba (#4882 Cell
Signaling), a-tubulin (Cell Signaling cat #2125), phospho-NF-kB p65 (cat #3039
Cell Signaling), Total p65 (cat #4764 Cell Signaling ), p100/52 (cat #4882 Cell
Signaling), MHC-MF20 (Developmental Studies Hybridoma Bank, Iowa City, IA)
and myogenin-F5D (Developmental Studies Hybridoma Bank, Iowa City, IA). For
loading controls, the membranes were stripped and reprobed with a-tubulin (cat #
2125 Cell Signaling). Proteins were visualized using the SuperSignal
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chemiluminescence reagent substrate(Pierce) and Biorad Chemdoc system.
Densitometry, that is, area  density analysis was quantified with Quantity One
4.5.2 1-D Analysis Software (Bio-Rad, Hercules, CA). For each experimental group,
a ratio of phosphorylated protein to total protein or a ratio of each protein to
a-tubulin was calculated and normalized to control.
Total RNA was isolated using Qiazol (Qiagen) and RNeasyMini Plus kit
(Qiagen, Valencia, CA). The yield and purity of the total RNA was assessed by
measuring the absorbance at OD260 and OD280 with the Nanodrop 2000
(Thermoscientific). The ratio of A260/A280 for all RNA samples was between 1.8
and 2.0, which indicated that the quality and purity of RNA was adequate for
subsequent cDNA synthesis. The extracted total RNA was reverse transcribed to
first strand cDNA using High Capacity RNA-to-cDNA kit (Life Technologies,
Carlsbad, CA). PCR and analysis were performed on the StepOne Plus detection
systems and software (Life Technologies). Each sample was run in triplicate. Data
normalization was accomplished by using 18S or GAPDH as the endogenous
control. The relative expression of target genes was expressed as fold change
between reference control and experimental groups. The primer pairs used were,
mouse 18S: sense CCCTGCCCTTTGTACACACC and antisense CGATCCGAGG
GCCTCACTA and mouse FN14: sense GACCTCGACAAGTGCATGGA and
antisense CGCATCCCAGGCAGAAGT. PCR was performed using Fast SYBRG.
For mRNA analysis of Aldob (sense: AGA GCA TCG GCG GAG TGA, antisense:
TTT CCC TGG CTG TCC TTC TG), Galm (sense: TGC TTG GCT TTG CGG
AAT, antisense: CCC AAC CAC TGC TCC AAA GT) Hk2 (sense: GCC AAG
CGT CTC CAT AAG G, antisense: CGG AGG AAG CGG ACA TCA) and M1 and
M2 transcripts Taqman Inventoried gene expression probes were ordered from Life
Technologies. PCR reactions were performed using TaqMan Fast Universal PCR
Master Mix.
Mitochondria isolation and respiration measurements. Mitochondria were
isolated from the ischaemic and NIL of WT and CD163 / mice after HLI or
from one limb after high-dose TWEAK infusion into CD163 / mice by
differential centrifugation techniques39. Oxygen consumption of isolated
mitochondria was monitored using a Clark-type oxygen electrode (Hansatech
Instruments, Amesbury, MA). Respiratory capacity was assessed by measuring
State 3 (that is, ADP-dependent) and State 4 (that is, ADP-independent)
respiration, using glutamate/malate as the oxidizable substrate. The respiratory
control ratio was calculated as the ratio of states 3 and 4 respiration rates
(i.e., states 3 divided by 4 respiration).
Bone marrow-derived macrophage (BMM) isolation. Eight-week-old
CD163 / mice and littermate WT mice were used for bone marrow extraction
and subsequent macrophage isolation. Muscle tissue was removed from the bones
using scissors and bones were cut at both ends to free the marrow. Bones were
flushed with RPMI (þ glutamine) medium supplemented with antibiotics. The
bone marrow cells were triturated to bring the cells into single cell suspension. The
slurry was then filtered using a sterile 70 mM nylon strainer to remove debris. Cells
were centrifuged at 200g for 3 min. The supernatant was aspirated, and the cells
were resuspended in RBC Lysis buffer (eBioscience) to lyse the RBC for 5 min. The
cells were then resuspended and washed three times with BMM medium (that is,
RPMI medium with glutamine (cat#11875-093 Life Technologies), supplemented
with 10% FBS (Atlanta Biologicals) and 1% Penicillin/Streptomycin (Life Tech-
nologies)). Bone marrow cells were counted using an automated cell counter. The
cell concentration was adjusted to 4 107 cells ml 1 in BMM medium. Cells were
seeded in a six-well plate (Falcon) and incubated in a humidified incubator with 5%
CO2 at 37 C. Media was changed twice, at 6 and 24 h after seeding, at which time
media was supplemented with 40 ng ml 1 macrophage colony-stimulating factor
(m-CSF) (cat#14-8983 eBioscience). Cells were incubated at 37 C and differ-
entiated into macrophages in BMM-mCSF medium for 7 days.
Cell culture. Mouse Dermal microvascular Endothelial Cells (MDEC) (cat#C57-
6064 Cell Biologics) were used at passages 3 through 8. Cells were grown in
complete growth medium (CGM) (cat #M1168 Cell Biologics). Cells were cultured
on gelatin (Cell biologics) coated tissue culture dishes. Murine C2C12 cells
(cat#CRL-1722 ATCC) were used at passages 2 through 10 and cultured in
complete growth media (DMEM supplemented with 20%FBS (Atlanta Biologicals)
and 1% Penicillin and streptomycin (Life Technologies)).
TWEAK stimulation. For stimulation experiments in MDEC cells were washed
one time with 1 PBS and then incubated overnight with low (10 ng ml 1) and
high dose (150 ng ml 1) of mouse recombinant His tagged TWEAK (R&D), in
Basal Endothelial Media (BM) (Cell Biologics) supplemented with 5% fetal bovine
serum.
For stimulation in murine C2C12 cells, cells were washed one time with
1 PBS and then incubated with low (10 ng ml 1) and high dose (100 ng ml 1) of
mouse recombinant TWEAK for 2 h in differentiating media (DM) (that is, DMEM
(ATCC) supplemented with 2% Horse serum(ATCC) and antibiotics). After
exposure to TWEAK at the indicated doses and times, whole-cell lysates were
subjected to immunoblotting as described below.
For experiments shown in Fig. 6c, mouse recombinant TWEAK (untagged) was
obtained from Kingfisher Biotech.
Macrophage supernatant experiments. MDEC were plated in six-well plates
(Falcon) at a concentration of 2.5 105 cells ml 1 and incubated overnight in
CGM. The next day media was aspirated and cells were treated with 7-day m-CSF-
treated BMM supernatants obtained from WT and CD163 / differentiated
BMMs. Each well was treated with WT supernatant or CD163 supernatant.
Treatment lasted 3 h. Cells were harvested for immunoblotting using techniques
and antibodies described below.
Cell proliferation assays. C2C12 cells were seeded at 2 103 cells per well in GM
in a 96-well plate (Falcon) and incubated overnight at 37 C. The next day, cells
were washed once with 1 PBS and treated overnight with and without TWEAK
(cat#1237 R&D Systems) (100 ng ml 1) in DM. Cells were then pulsed with 10 mM
BrdU and incubated thereafter for 2 h. Media was removed and cells were fixed,
and processed per manufacturer protocol. Cellular proliferation was determined
immunochemically by detection of BrdU incorporated into newly synthesized
DNA into cells which is directly proportional to the magnitude of colour
development by using Calbiochem BrdU Cell Proliferation assay kit. Absorbance
was measured at wavelength of 450 nm. Results for each experiment were expressed
as fold change compared with the negative control, and the fold changes for three
independent experiments were then averaged.
MDEC were seeded at 4 103 cells per well and incubated in CGM in a 96-well
plate and incubated overnight at 37 C. Next day, Cells were washed once with
1PBS medium and replaced with BM supplemented with 5% FBS. Cells were
treated or not treated with TWEAK (150 ng ml 1) overnight before pulsing with
10 mM BrdU. Cellular proliferation was determined by measurement of BrdU using
Calbiochem BrdU Cell Proliferation assay as described above.
Proliferation assay and siRNA transfection. C2C12 cells were seeded at a
concentration of 1 104cells per well in GM on day 0. On day 1 the cells were
transfected with scrambled Stealth RNAi siRNA duplex (36% GC) (negative)
(proprietary sequence) or stealth P65siRNA GCAGAAAGAAGACAUUGAGG
UGUAU, or stealth RBPJ siRNA CCAUUACGGGCAGACUGUCAAGCUU, (Life
Technologies) using Lipofectamine 3000 (Life Technologies) as per manufacturer’s
protocol. Transfection was preformed in Optimem (Life Technologies).
Transfection complexes were removed after 6 h and replaced with GM. Twenty-
four hours after transfection, that is, day 2 the media was aspirated, cells were
washed 1 PBS followed by addition of DM and treated or not treated with
100 ng ml 1 TWEAK recombinant protein overnight. Forty-eight hours post
transfection, transfected cells were pulsed with 10 mM BrdU and incubated for 2 h.
Cellular proliferation was determined as described above.
MDEC were seeded 1 105 cells per ml and incubated in regular growth
medium in a 96-well plate and incubated overnight at 37 C. Next day cells were
transfected with scrambled stealth siRNA or stealth P65 siRNA and RBPJ siRNA
(sequences provided above) using Lipofectamine 3000 (Life Technologies) and
Optimem. Transfection complexes were removed after 6 h and replaced with CGM.
24 h post transfection, media was aspirated and the cells were washed with 1PBS,
followed by addition of 5% FBS in basal medium to the cells and treated or not
treated with 150 ng ml 1 TWEAK recombinant protein for overnight. 48 h post
transfection cells were then pulsed with 10 mM BrdU and incubated for 6 h. Cell
proliferation was assayed as described above.
All siRNA sequences were validated in MDEC using western blots
demonstrating 480% knockdown (Supplementary Fig. 16).
Western blotting. Whole-cell lysates were prepared by resuspending the cell pellet
in ice-cold RIPA lysis buffer supplemented with Protease inhibitors (Roche) and
10 mm PMSF and incubated at 4 C for 20 min. Lysates were then clarified by
centrifugation at 4 C for 15 min. Protein concentrations were estimated using the
BCA Protein Assay Kit (Pierce). Equal amounts of protein extract (B100 ug) were
subjected to SDS-polyacrylamide gel electrophoresis and electrotransferred onto
PVDF membranes Blocking was performed using 1Casein blocking buffer in
1TBST. Membranes were then probed with primary antibodies diluted in 5%
bovine serum albumin in 1TBST, and incubations proceeded O/N at 4 C.
Primary antibodies used were as mentioned above. The membranes were then
washed three times in TBST for 5 min each and then incubated in TBST/1Casein
containing a 1:1,000 dilution of horse radish peroxidase-conjugated goat anti-
rabbit IgG- secondary antibodies, for 1 h at room temperature. The membranes
were again subjected to three washes in TBST for 5 min each times. HRP was
detected using the SuperSignal chemiluminescence reagent substrate (Pierce)
and signal was visualized on the Biorad Chemdoc system. All experiments were
performed at least three times. Full images of immunoblots are shown in
Supplementary Figs 17–23.
Analysis of Notch activation after TWEAK stimulation following p65 knockdown.
MDEC were seeded at 1 106 per 100 mm dish cultured at 37 C in CGM overnight.
C2C12 cells were seeded at 4 105 per 100 mm dish cultured at 37 C in GM over-
night. Both C2C12 and MDEC were transfected with scrambled stealth RNAi siRNA
duplex (36% GC) (negative) (proprietary sequence) and stealth P65siRNA GCAGA
AAGAAGACAUUGAGGUGUAU using Lipofectamine 3000 and Optimem. Trans-
fection complexes were left for 6 h before removal and replaced with CGM/GM. The
transfected MDEC were then treated the next day with 5%FBS in BM and nothing or
150 ng ml 1 TWEAK for 24 h. The cells were harvested for western blot 48 h after
transfection. The transfected C2C12 cells were treated 48 h post transfection with DM
and with TWEAK (100 ng ml 1) or nothing for 2 h. Immunoblotting was then per-
formed on whole-cell lysates as described above.
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ELISA. TWEAK concentrations were measured in plasma obtained from both
genotypes of mice without HLI, 3, 14 and 28 days after HLI using commercial
mouse TWEAK ELISA (cat#MBS721908, MyBiosource, n¼ 5). Similarly sCD163
concentrations were measured by obtaining plasma from both genotypes of mice
without HLI, 3, 14 and 28 days after HLI using commercial mouse sCD163 ELISA
(cat#MBS725142, MyBiosource, n¼ 5). All experiments were conducted according
to manufacturer’s directions.
TWEAK binding ELISA. Recombinant mouse sCD163 (cat#7435 R&D Systems)
and recombinant soluble Fn14/TWEAKR (cat#310-21Peprotech) were coated onto
96-well microtiter plate (Linbro MP Biomedicals) at a concentration of 1 mg ml 1
in bicarbonate/carbonate buffer (pH 9) overnight at 4 C. VEGFR1 (cat#10136-
H08H Life technologies) was used as a negative control. Wells were blocked with
blocking buffer (Pierce) in phosphate buffered saline with 0.05% Tween 20 (PBST)
for 1 h. PBST was used as wash buffer. Mouse soluble TWEAK (cat#1237 R&D
Systems) was then added to the wells at 0.4 mg ml 1 for 30 min, at room tem-
perature. The wells were washed three times using PBST. The binding of TWEAK
to CD163/Fn14 was detected by ELISA using a biotinylated anti-mouse TWEAK
antibody (cat#BAF1237 R&D Systems) diluted according to manufacturer’s
directions followed by PBST rinses repeated three times. To detect the biotinylated
TWEAK antibody a HRP enzyme conjugated Streptavidin recombinant protein
(cat#554066 BD Pharmingen) was added for 30 min at a 1:1,000 dilution. This step
was again followed by triplicate PBST rinses. Bound HRP enzyme conjugate was
detected using TMB (Pierce) as substrate for 15 min, and 2 N H2SO4 as the stop
solution. Absorbance was measured using an automated plate reader at a
wavelength of 450 nm.
To confirm coating of the proteins parallel ELISAs were performed using
corresponding antibodies anti CD163 (M-96) (sc-33560 Santacruz) and anti FN14
(cat#4403 Cell Signaling) followed by an HRP-conjugated anti-rabbit secondary
antibody. Coated proteins were detected using TMB as substrate as described
above.
To further confirm specificity of binding of the detection antibody, nothing or
recombinant mouse TWEAK was added to uncoated pre-blocked wells during the
experiment followed by the addition of biotinylated anti-mouse TWEAK antibody.
The HRP conjugate Streptavidin was then added as stated above. There was no
significant difference in signal generated from these experiments. This ruled out
non-specific binding of the detection antibody and of recombinant TWEAK.
To rule out that detection of TWEAK using an anti-TWEAK antibody might in
some way be affected by TWEAK binding to CD163 or FN14, wells were coated
with TWEAK (0.4 mg ml 1). CD163 (1 mg ml 1) and FN14 (1mg ml 1), or
nothing was added to the blocked TWEAK-coated wells for 1 h. Wells were washed
as per protocol. Detection of TWEAK using anti-TWEAK antibody revealed no
differences in optical density between groups suggesting that binding of TWEAK to
either receptor does not influence the detection method.
For experiments showing dose-dependent TWEAK binding to recombinant
mouse sCD163 and recombinant soluble FN14, individual wells were coated with
CD163 (1mg ml 1)and Fn14(1 mg ml 1). Wells were first blocked and increasing
concentrations of untagged recombinant mouse TWEAK (Kingfisher Biotech) (0,
3, 10, 30, 100, 300 and 1,000 ng ml 1) were added to the wells for 30 min at room
temperature followed by biotinylated anti-TWEAK and HRP-conjugated
Streptavidin as described earlier.
Serum immunoprecipitation. Pierce Co-Immunoprecipitation kit Cat# 26149 was
used for the Co-Immunoprecipitation of the Tweak-CD163 complex from serum.
All steps were performed as per kit protocol. Affinity purified anti-TWEAKpAb
(ALX-210-926 Enzo Life Sciences) was cross-linked to AminoLink Plus coupling
Resin. Normal Rabbit IgG (cat#sc-2027 Santacruz) was used instead of the
TWEAK antibody as an isotype control. 2.2 ml of pooled mouse serum was mixed
in a 1:1 ratio with 2 PBS along with protease inhibitors (Roche), and then
introduced to the Anti-TWEAK cross-linked beads after which the antibody–
antigen complex was gently shaken overnight at 4 C using an end over end rotator.
Co-immunoprecipitated protein complexes were eluted with given elution buffer.
Samples were mixed with 4 sample buffer supplemented with 20 mm dithio-
threitol and heated at 95 C for 5 min followed by centrifugation at 13,000 r.p.m.
for 2 min at 4 C before applying onto a 4–15% TGX gel (Biorad) Membranes were
probed using an anti CD163(M-130) (cat#bs2525R Bioss Antibodies) and anti
TWEAK pAb (Enzo). Recombinant mCD163 (R&D) was used as positive control.
Analysis of angiogenesis in the postnatal mouse retina. To analyze retinal
vascular pattern and to preserve intact endothelial filopodia and sprouts at the
angiogenic front, whole animal eyes were fixed in 4% paraformaldehyde 4 C
overnight. After washing with PBS, retinas were dissected and permeabilized in
PBS, 1% BSA, and 0.5% Triton for 2 h at 4 C. After blocking/permeabilization,
retinas were incubated in FITC-conjugated isolectin B4 (Cat.#L2895, Sigma) for
24 h at 4 C. For DLL4 detection, an antibody against DLL4 (cat# AF1389R&D
Systems)was used. The following day, the retinas were washed in PBS before the
retinas were partially cut in four quadrants to allow subsequent flat mounting with
Vectashield mounting medium (Vector Labs, Burlingame, CA). All of the images
shown are representative of the vascular phenotype observed in at least ten retinas
from five pups. All quantifications were done with NIS-elements v3.0 (Nikon) on
high-resolution confocal images. The ratio of the isolectin-B4-positive area to the
total area was calculated and defined as a percentage. Vascular progression was
measured by defining a straight line from the angiogenic front to the centre of the
retina. The number of filopodial extensions was quantified at the retina angiogenic
front. The total number of filopodia was normalized for a standard endothelial
vessel length of 1 mm that was measured and defined according to published
protocols40. Branchpoint is assessed as the number per 200 200 um field.
Statistics. Analysis of equal variances was performed using an O’Brien test. Ana-
lysis of normality of continuous variables was performed using the Kolmogorov–
Smirnov test. Normally and non-normally distributed data were analysed for sig-
nificance by student’s t-test or Mann–Whitney–Wilcoxon tests, respectively. For
mouse experiments, we estimated that a sample size of five mice per group with an
expected difference of roughly 40% in terms of end point with a standard deviation
of 15% would provide 490% power to detect a differences between groups using a
two-sided alpha of 0.05. For quantification of other studies presented, a minimum of
4 replicates were tested for each condition of experiment. The data are represented as
mean and s.e.m. Comparisons between groups were achieved using a two-sided
student’s t-test. For multiple group comparisons, we utilized a one-way analysis of
variance (ANOVA). If the variance ratio test (F-test) was significant, a more detailed
post hoc analysis of differences between groups was made using a Tukey–Kramer
honest significance difference test. For analysis of running distance, a two-way
ANOVA was used to analyze differences. The P value for interaction between the
two groups (mouse genotype and procedure (that is, HLI versus sham) was 0.03.
Differences were deemed to be statistically significant for P values of o0.05. One
animal in the running wheel experiment (Supplementary Fig. 2b) in CD163 HLI
group was excluded when it was found his cage was not functioning properly. No
other animals were excluded from the analyses.
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